China's 15th Five-Year Plan is poised to reshape the pharmaceutical landscape, with significant implications for market access, supply chains, and competitive positioning.

Central to the plan is China's "AI+" strategy, which aims to accelerate industrial modernization by embedding artificial intelligence across healthcare, drug development, and biomanufacturing. These efforts are strengthening domestic innovation capabilities, expanding industrial capacity, and intensifying competition for critical talent, technology, and intellectual property.

Join Strider's intelligence analysts for a briefing on the strategic implications of China's next development cycle. We'll examine how evolving policy priorities could affect commercial operations, supply chain resilience, IP protection, and the growing competitive influence of China's domestic pharmaceutical sector.